MedWatch

CHMP gives positive opinion on Genmab partner's lung cancer drug

Janssen has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), including a recommendation that its candidate, amivantamab, is conditionally approved in Europe.

Photo: Tuala Hjarnø / Genmab / PR

Genmab's US partner, Janssen, has received a positive opinion from the CHMP, a committee that is part of the European Medicines Agency, and a recommendation that its candidate receives conditional marketing authorization in Europe for the treatment of non-small cell lung cancer. The dug is called amivantamab, with the commercial name Rybrevant.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs